Figure 4 | Scientific Reports

Figure 4

From: Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema

Figure 4

Number of injections received over 24 months according to baseline BCVA and treatment cohort in the overall FAS. Data are for all patients in the FAS with follow-up data on treatment exposure available to at least 23 months (i.e., with an injection between 23 and 25 months from the first IVT-AFL treatment). BCVA, best-corrected visual acuity; FAS, full analysis set; IVT-AFL, intravitreal aflibercept.

Back to article page